Arpita Desai

@sophiemerrick1 just presented patient-reported outcomes from the RAMPART trial, comparing adjuvant durvalumab + tremelimumab (DT) vs active monitoring (AM) in resected intermediate/high-risk RCC. - At week 16: DT showed significantly worse overall health and quality of life (p=0.0008), role function (p=0.04), fatigue (p=0.002), and insomnia (p=0.02). - At month 15: Pain and cognitive function remained worse in the DT arm. Important to weigh safety alongside the DFS benefit. #GU26 #RCC @OncLive @OncoAlert @OncBrothers

⁦@HHammersMD⁩ discussing ⁦@KCPUTSW⁩ spinoff #belzutifan @ASCO #GU26

Great overview by @PavlosMsaouel at #GU26 on clinical trial design. Highlighting the work of Think Tank group at IKCS!! @KidneyCancer

Congrats to @NazliDizman on her RCC posters studying grade 4 RCC outcomes with nivo + ipi and an ongoing trial of ivonescimab #ASCOGU26 @MDAndersonNews

The KIM-1 story continues with this joint effort between @DanaFarber_GU @VincentWenxinXu and @MDAndersonNews @ChadTang presented the K-COMPASS model, integrating circulating KIM-1 + ctDNA MRD to risk-stratify oligometastatic ccRCC treated with MDT. - KIM-1 and ctDNA independently associated with systemic therapy-free survival (baseline and 3 mo) - Higher KIM-1 tracked with worse outcomes (baseline PFS HR 2.2 / OS HR 5.1; 3-mo PFS HR 3.5 / OS HR 5.0) - Model performance: C-index 0.76; online tool available (trialdesign.org) Promising integrated blood-based + clinical risk model for risk-adapted decisions. Happy to share that the full publication is now available on @EUplatinum: 10.1016/j.eururo.2026.01.004 #GU26 #RCC @OncoAlert

@lalaniMD presenting cytoshrink data at #guasco26. IIT random metastatic rcc to +\- radiation with Nivo/ipi. No difference in outcomes however imbalances in study population and high freq of non ablative doses. Congrats to the study team for conducting this study.

Great sessions at ASCO GU for kidney cancer including dropping K-COMPASS, updates on clinical trial approaches, and LITESPARK-022 @ejasonabel @PavlosMsaouel @ChadTangMD @KidneyCancer #josekaram

@HHammersMD discusses novel targets in kidney cancer. The future of kidney cancer is expanding beyond VEGF & PD-1. 🚀 A rich pipeline of novel targets and immune strategies in RCC: • HIF inhibitors & next-gen combinations • Bispecific antibodies (VEGF/PD-1, PD-L1/CTLA-4) • BiTEs (e.g., ENPP3/CD3) • CAR-T (CA9, CD70) • Small molecule immune modulators (PTPN2, HPK1) • mRNA vaccines (V940) 📈 We’re entering an era of combination proliferation — with the promise of higher efficacy… ⚖️ …and the responsibility to manage added toxicity. The next chapter in RCC is precision layering of biology. #RCC #ASCOGU26 @OncoAlert @GUOncologyNow @OncLive

Excellent talk by @ShuchiGulati summarizing the current state of the art of imaging in RCC #ASCOGU26

@DrBenTran w @ANZUPtrials #CLIMATE careful prospective eval of miR-371 for germ cell tumor. Prognostic & can stratify pts. Still not uniform in testing and cutoffs but moving needle. @ASCO #GU26 @OncoAlert @urotoday

Excellent summary by @katy_beckermann 👏 📉 DFS signal with adjuvant HIF-2α + PD-1 in high-risk ccRCC 🧬 Strong biologic rationale for HIF targeting 🔄 Emerging role in post–PD-1 metastatic RCC ⚖️ Patient selection is key Thoughtful synthesis of biology, sequencing, and patient selection. #ASCOGU26

Combination therapy is emerging as a standard in refractory RCC. Combos increase tumor shrinkage endpoints. TKI provides early disease control. CRs are possible but is cure? Toxicity consideration is critical in this setting. Biomarkers to guide choice of drug(s) are needed

📊 Primary endpoint met. DFS improved with pembro + belzutifan: 📉 HR 0.72 (95% CI 0.59–0.87) 📈 24-mo DFS 80.7% vs 73.7% Absolute ~7% improvement at 2 years. Clinically meaningful signal. ⏳ OS immature at interim analysis. ⚠️ Higher grade ≥3 AEs: 52% vs 30% Anemia and hypoxia notable. Safety consistent with known profiles — but toxicity discussion will matter in the adjuvant setting. Adjuvant RCC is moving toward biologic layering — patient selection will be key. #ASCOGU2026 @DrChoueiri @urotoday @OncoAlert @GUOncologyNow

🚨 LITESPARK-022 at #ASCOGU2026 Adjuvant intensification in high-risk ccRCC post-nephrectomy: pembro + belzutifan vs pembro alone. Can targeting hypoxia improve cure rates? 🧬 #RCC @DrChoueiri @urotoday @OncoAlert @GUOncologyNow

🚨 LITESPARK-011 at #ASCOGU2026 Belzutifan + lenvatinib vs cabozantinib post–PD-(L)1 in advanced ccRCC: 📉 Median PFS 14.8 vs 10.7 mo 📊 HR 0.70 📈 ORR 52.6% vs 40.2% OS trending but not yet significant. HIF-2α + VEGF shows real activity in the post-IO space. #RCC @OncoAlert @GUOncologyNow @urotoday

📍 Day 3️⃣ at #ASCOGU2026 Kidney Cancer Oral Abstracts happening now 🎤🧬 Biology, sequencing, and strategy converging in RCC. The field is moving beyond activity — toward precision and patient selection. #ASCOGU26 #RCC @oncoalert

⭐ Coming soon: a new roundtable series on metastatic #RCC featuring panelists @DrChoueiri, @montypal, David McDermott, @ADESAIONCMD, @DrVaishampayan, and @Daniel_J_George!

Extraordinary group who have worked so hard to put together this year’s robust conference-Well done!👏 Thank you for your generosity of time and talents 🙏🏻🧡

Grateful to the @IKCancerSummit @kidneycancer community for an inspiring meeting and the opportunity to speak on advancing care in refractory RCC! 🎤💙✨ Always incredible to be surrounded by colleagues who push the field forward. 🔬🌍 Also proud to share our poster on Equity in Genomic Integration and Outcomes in DDR-mutant mRCC. 🧬📊 Equity isn’t optional — it’s essential to true progress. ✨🤝 Leaving IKCS energized, motivated, and ready to keep driving innovation, inclusion, and hope for every RCC patient. 💪🌟💙

Hear from @ZakhariaYousef, Planning Committee Co-Chair, as he reflects on what truly sets #IKCSNA25 apart — a unique and meaningful gathering for the #kidneycancer community 🤝🔬🧡 @MayoClinic